MedTrace Logo

Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

NCT03085056 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2025-07-03

No results posted yet for this study

Summary

The purpose of this study is to test the safety and tolerability of this treatment combination of paclitaxel and trametinib. Additionally, this study aims to to find out what effects the combination of paclitaxel and trametinib has on the shrinkage and growth of anaplastic thyroid cancer.

Conditions

  • Anaplastic Thyroid Cancer

Interventions

DRUG

Trametinib

trametinib orally 2mg daily during each 4 week cycle

DRUG

Paclitaxel

paclitaxel 80mg/m\^2 weekly for 3 out of 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Eric Sherman, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-15
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03085056 on ClinicalTrials.gov